Soiken Holdings Inc. (2385) AI Stock Analysis

• Market Cap: ¥4.89B
• Dividend Yield: 2.67%
• Average Volume (3M): 237.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: -6.01%
• EPS Growth: 68.18%
• Country: JP
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.31
• Shares Outstanding: 26,158,200
• 10 Day Avg. Volume: 110,230
• 30 Day Avg. Volume: 237,016
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Soiken Holdings Inc. faces substantial financial difficulties with declining revenues and negative profitability, despite a strong balance sheet. The technical indicators point to a bearish trend, and the valuation metrics further highlight the company's struggles. These factors combine to yield a low overall stock score, emphasizing the need for strategic operational improvements.

Soiken Holdings Inc. Business Overview & Revenue Model

Company Description

Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.

How the Company Makes Money

Soiken Holdings Inc. generates revenue through a multi-faceted business model centered around its healthcare and pharmaceutical services. The company earns income from the development and sale of health supplements and functional foods, which are distributed through various retail and online channels. Additionally, it provides healthcare consulting services, which contribute to its revenue streams. Partnerships with other healthcare companies and institutions play a significant role in expanding its market reach and enhancing its product offerings, thereby increasing its earnings potential.

Soiken Holdings Inc. Financial Statement Overview

Summary

Soiken Holdings Inc. is experiencing significant financial challenges due to declining revenues and profitability issues. While the balance sheet shows strength with zero debt and substantial equity, negative cash flows and profitability metrics indicate operational inefficiencies.

Income Statement

Soiken Holdings Inc. has experienced a significant decline in revenue, with a notable revenue growth decline of -38.01% from the previous year in the TTM period. The company is facing challenges with its profitability, as indicated by negative net profit and EBIT margins, suggesting operational inefficiencies or high costs relative to revenue.

Balance Sheet

The balance sheet shows strong equity and no debt, which indicates a solid financial foundation. The equity ratio is healthy, highlighting the company's reliance on equity financing. However, the return on equity has declined significantly due to negative net income, which is a concern for long-term sustainability.

Cash Flow

The company struggles with cash flow generation, as evidenced by negative free cash flow and operating cash flow in recent periods. The absence of free cash flow growth indicates challenges in converting revenue into cash, which is crucial for operational stability and potential investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.00B	4.85B	5.16B	8.08B	9.35B	8.94B
Gross Profit	2.52B	2.41B	2.48B	3.72B	4.26B	4.11B
EBITDA	-204.90M	-201.93M	-583.21M	750.07M	1.23B	948.13M
Net Income	-237.60M	-210.70M	-662.20M	451.85M	809.71M	562.06M
Balance Sheet
Total Assets	6.78B	6.81B	6.95B	8.24B	8.49B	7.15B
Cash, Cash Equivalents and Short-Term Investments	5.03B	5.26B	4.79B	5.95B	6.22B	4.26B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	680.07M	775.16M	697.02M	1.07B	1.64B	915.00M
Stockholders Equity	6.08B	6.02B	6.23B	6.97B	6.65B	6.04B
Cash Flow
Free Cash Flow	0.00	521.19M	-895.42M	-141.08M	2.09B	-131.65M
Operating Cash Flow	0.00	557.96M	-880.82M	-101.55M	2.14B	-107.44M
Investing Cash Flow	0.00	-389.41M	-14.29M	160.37M	-244.58M	-24.85M
Financing Cash Flow	0.00	-214.00K	-260.71M	-130.21M	-129.94M	-131.25M

Soiken Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 190.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Neutral. The current price of 190 is below the 20-day moving average (MA) of 190.65, above the 50-day MA of 175.42, and above the 200-day MA of 148.10, indicating a neutral trend. The MACD of 3.59 indicates Positive momentum. The RSI at 51.02 is Neutral, neither overbought nor oversold. The STOCH value of 25.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2385.

Soiken Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	83 Outperform	2.30T	12.41	12.51%	2.16%	4.04%	21.20%
4519	76 Outperform	11.05T	27.97	19.92%	1.58%	10.29%	11.37%
2181	76 Outperform	643.06B	18.63	18.92%	3.37%	7.71%	3.01%
4547	71 Outperform	179.52B	15.19	5.72%	2.04%	15.40%	7.73%
2385	43 Neutral	¥4.89B	―		2.67%	-6.01%	68.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%